Impact of Meningococcal Serogroup C Conjugate Vaccines on Carriage and Herd Immunity
Author(s) -
Martin Maiden,
Ana Belén Ibarz-Pavón,
Rachel Urwin,
Stephen J. Gray,
Nicholas Andrews,
Stuart C. Clarke,
A M Walker,
M.R. Evans,
J. Simon Kroll,
Keith Neal,
Dlawer A. A. Ala’Aldeen,
Derrick W. Crook,
Kathryn Cann,
Sarah Harrison,
Richard Cunningham,
David Baxter,
Edward B. Kaczmarski,
Jenny MacLennan,
J. Claire Cameron,
James M. Stuart
Publication year - 2008
Publication title -
the journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.69
H-Index - 252
eISSN - 1537-6613
pISSN - 0022-1899
DOI - 10.1086/527401
Subject(s) - carriage , herd immunity , medicine , neisseria meningitidis , meningococcal vaccine , vaccination , serotype , virology , immunity , conjugate vaccine , immunology , immunization , biology , antibody , immune system , genetics , pathology , bacteria
In 1999, meningococcal serogroup C conjugate (MCC) vaccines were introduced in the United Kingdom for those under 19 years of age. The impact of this intervention on asymptomatic carriage of meningococci was investigated to establish whether serogroup replacement or protection by herd immunity occurred.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom